Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veltuzumab and/or epratuzumab with UKALL12 chemotherapy in relapsed B-precursor acute lymphoblastic leukemia
ISRCTN15257573Phase 2Completed
- Sponsor
- Queen Mary University of London
- Start
- Jan 2010
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of veltuzumab and epratuzumab in acute lymphoblastic leukemia (ALL) (3 cohorts), sponsored by Queen Mary University of London. Primary endpoint: Safety and tolerability. Started Jan 2010; status: completed.
02
Drugs
veltuzumabepratuzumab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ISRCTN15257573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15257573.